USOO8883832B2 (12) United States Patent (10) Patent No.: US 8,883,832 B2 Shallwitz et al. (45) Date of Patent: *Nov. 11, 2014 (54) COMPOUNDS, COMPOSITIONS, AND (2013.01); C07D 277/60 (2013.01); A61 K METHODS FOR PREVENTING METASTASS 31/538 (2013.01); A61K 31/428 (2013.01); OF CANCER CELLS A61K 45/06 (2013.01); A61 K3I/7068 (2013.01) (71) Applicant: Aerpio Therapeutics Inc., Cincinnati, USPC ....................... 514/365: 514/254.02: 514/342 OH (US) (58) Field of Classification Search (72) Inventors: Robert Shalwitz, Bexley, OH (US); None Kevin Gene Peters, Cincinnati, OH See application file for complete search history. (US) (56) References Cited (73) Assignee: Aerpio Therapeutics Inc., Cincinnati, OH (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 4,673,641 A 6/1987 George et al. 5,424,398 A 6/1995 Middeldorp et al. patent is extended or adjusted under 35 5,585,089 A 12/1996 Queen et al. U.S.C. 154(b) by 0 days. 5,688,781 A 1 1/1997 Siegallet al. 5,807,819 A 9/1998 Cheng et al. This patent is Subject to a terminal dis 5,994,128 A 11/1999 Fallaux et al. claimer. 6,033,908 A 3/2000 Bout et al. 6,342,219 B1 1/2002 Thorpe et al. (21) Appl. No.: 13/783,311 6,589,758 B1 7, 2003 Zhu 6,596,772 B1 7/2003 Huang et al. (22) Filed: Mar. 3, 2013 7,226,755 B1 6/2007 Peters et al. 7,507,568 B2 3/2009 Evdokimov 7,588,924 B2 9, 2009 Evdokimov et al. (65) Prior Publication Data 7,589,212 B2 9/2009 Gray et al. US 2014/0249100A1 Sep. 4, 2014 7,622,593 B2 11/2009 Gray et al. 7,795,444 B2 9/2010 Gray et al. 8, 106,078 B2 1/2012 Gray et al. Related U.S. Application Data 8,188,125 B2 5/2012 Gray et al. 8,258,311 B2 9/2012 Gray et al. (63) Continuation of application No. 12/677.550, filed as 8.329,916 B2 12/2012 Amarasinghe et al. application No. PCT/US2010/020822 on Jan. 12, 8.338,615 B2 12/2012 Gray et al. 2010, now Pat. No. 8,569,348. 2004O1671.83 A1 8/2004 Klopfenstein et al. 2004/0204863 A1 10/2004 Kim et al. (60) Provisional application No. 61/223.260, filed on Jul. 6, 2007/02991 16 A1 12/2007 Gray 2009. 2008.0004267 A1 1/2008 Gray 2008/0076764 A1 3/2008 Peters et al. 2008. O1086.31 A1 5/2008 Gray et al. (51) Int. Cl. 2009/0227639 A1 9/2009 Gray et al. AOIN 43/78 (2006.01) A6 IK3I/425 (2006.01) (Continued) A6 IK3I/427 (2006.01) A6 IK3I/53 (2006.01) FOREIGN PATENT DOCUMENTS CO7D 417/04 (2006.01) WO WOOOf 65085 11, 2000 C07D 277/64 (2006.01) WO WOOOf 65088 A1 11, 2000 CO7D 417/4 (2006.01) WO WOO2,26774 A1 4/2002 C07D 277/28 (2006.01) C07D 417/12 (2006.01) OTHER PUBLICATIONS A 6LX3L/2197 (2006.01) A6 IK3I/4245 (2006.01) Altschulet al., “Gapped BLAST and PSI-BLAST: A New Generation A6 IK3I/433 (2006.01) of Protein Database Search Programs.” Nucleic Acids Res., A6 IK3I/4439 (2006.01) 25(27).3389-3402 (1997). A6 IK3I/426 (2006.01) (Continued) C07D 277/60 (2006.01) A6 IK3I/538 (2006.01) A6 IK3I/428 (2006.01) Primary Examiner — Patrick Lewis A6 IK 45/06 (2006.01) (74) Attorney, Agent, or Firm — Richard S. Echler A6 IK3I/7068 (2006.01) (52) U.S. Cl. CPC ............ C07D 277/28 (2013.01); A61K3I/427 (57) ABSTRACT (2013.01); A61 K3I/513 (2013.01); C07D Disclosed are methods for preventing metastasis of cancer 417/04 (2013.01); C07D 277/64 (2013.01); cells. The disclosed compounds can be used to prevent the C07D 417/14 (2013.01); C07D 417/12 spread of tumor or other types of cancer cells. (2013.01); A61 K3I/497 (2013.01); A61 K 3 1/4245 (2013.01); A61 K31/433 (2013.01): A61 K3I/4439 (2013.01); A61 K3I/426 52 Claims, 5 Drawing Sheets US 8,883,832 B2 Page 2 (56) References Cited Itoh et al., “Purification and Characterization of the Catalytic Domains of the Human Receptor-Linked Protein Tyrosine U.S. PATENT DOCUMENTS Phosphatases HPTPB, Leukocyte Common Antigen (LCA), and Leukocyte Common Antigen-Related Molecule (LAR),” Journal of 2010, OO16336 A1 1/2010 Gray et al. 2011/0268694 A1 11/2011 Shallwitz et al. Biological Chemistry, 267(17): 12356-12363 (1992). 2012/O128625 A1 5, 2012 Shallwitz et al. Jones et al., “Development and Validation of a Genetic Algorithm for 2012/0129847 A1 5, 2012 Peters et al. Flexible Docking.” J. Mol. Biol., 267:727-748 (1997). Jones et al., “Molecular Recognition of Receptor Sites Using a OTHER PUBLICATIONS Genetic Algorithm with a Description of Desolvation.” J. Mol. Biol. 245:43-53 (1995). Annex et al., “Growth Factor-Induced Therapeutic Angiogenesis in Keen, “Radioligand Binding Methods for Membrane Preparations the Heart: Protein Therapy,” Cardiovascular Research, 65(3):649 and Intact cells.” Methods in Molecular Biology, 83: Receptor Signal 655 (2005). Transduction Protocols, edited Humana Press Inc., Totoway N.J. Ardeltet al., “Estradiol Regulates Angiopoietin-1 mRNA Expression (1997). Through Estrogen Receptor-O in a Rodent Experimental Stroke Köhler et al., “Continuous Cultures of Fused Cells Secreting Anti Model.” Stroke, 36:337-341 (2005). body of Predefined Specificity.” Biotechnology, 24:524-526 (1992). Auerbach et al., “Angiogenesis Assays: A Critical Overview.” Clini Krueger et al., “Structural Diversity and evolution of Human Recep cal Chemistry, 49:32-40 (2003). tor-Like Protein Tyrosine Phosphatases.” The EMBO Journal, Barany et al., “Solid-phase Peptide Synthesis: A Silver Anniversary 9(10):3241-3252 (1990). Report.” Int. J. Peptide Protein Res., 30 (6):705-739 (1987). Kugathasan et al., “Role of Angiopoietin-1 in Experimental and Bartlett et al., “Molecular Recognition in Chemical and Biological Human Pulmonary Arterial Hpertension.” Chest, 128:633-642 Problems; Cavet: A Program to Facilitate the Structure-Derived (2005). Design of Biologically Active Molecules.” Special Pub., Royal Kuntz et al., “A Geometric Approach to Macromolecule—Ligand Chem. Soc., 78:182-196 (1989). Interactions.” J. Mol. Biol. 161:269-288 (1982). Bohm, “The Computer Program LUDI: A New Method for the De Linet al., “Inhibition of Tumor Angiogenesis Using a Soluble Recep Novo Design of Enzyme Inhibitors.” J. Comuter-Aided. Molec. tor Establishes a Role for Tie2 in Pathologic Vascular Growth.” J. Clinical Invest...100(8): 2072-2078 (1997). Design, 6(1):61-78 (1992). Ma et al., “RNase Protection Assay.” Methods, 10(3):273-8 (1996). Bussolino, et al., “Molecular mechanisms of blood vessel formation.” Martin, "3D Database Searching in Drug Design.” J. of Medicinal Trends Biochem Sci. 22(7):251-256 (1997). Chemistry, 35(12):2145-2154 (1992). Carano et al., “Angiogenesis and Bone Repair. Drug Discovery Meadows, “Keeping Up with Drug Safety Information.” 2006: FDA Today, 8(21):980-989 (2003). Consumer Magazine: http://www.fda.gov/fdac/features/2006/306 Carvalho et al., “The Role of Angiogenesis in a Murine Tibial Model drugsafety.html, accessed Mar. 17, 2008. of Distraction Osteogenesis.” Bone, 34:849-861 (2004). Merrifield, “Solid Phase Peptide Synthesism. I. The Synthesis of a Chanteau et al., “Synthesis of Anthropomorphic Molecules: The Tetrapeptide.” J. Am. Chem. Soc., 85:2149-2154(1963). NanoPutians.” J. Org. Chem. 68:8750-8766 (2003). Miranker et al., “Functionality Maps of Binding Sites: A Multiple Cohen et al., “Molecular Modeling Software and Methods for Copy Simultaneous Search Method.” Proteins: Struc. Func. and Medicinal Chemistry.” J. Med. Chem., 33(3):883-894 (1990). Genectics, 11(1):29-34 (1991). Daar, “Perspective: Emerging Resistance Profiles of Newly Navaza, “AMoRe: An Automated Package for Molecular Replace Approved Antiretroviral Drugs.” Topics in HIV Medicine, 16(4): 110 ment.” J. Acta Cryst. A50: 157-163 (1994). 116 (2008). Nguyen et al., “Cellular Interactions in Vascular Growth and Differ Dean, “Recent Advances in Drug Design Methods: Where Will They entiation.” Int. Rev. Cytol., 204:1-48 (2001). Lead?” BioEssays, 16(9):683-687 (1994). Nishibata et al., “Automatic Creation of Drug Candidate Structures Fachinger et al., “Functional Interaction of Vascular Endothelial Based on Receptor Structure. Starting Point for Artificial Lead Gen Protein-Tyrosine Phosphatase with the Angiopoietin Receptor Tie eration.” Tetrahedron, 47(43):8985-8990 (1991). 2.” Oncogene, 18:5948-5953 (1999). O'Reilly, "Angiostatin: a novel angiogenesis inhibitor that mediates Flower, “Modelling G-Protein-Coupled Receptors for Drug Design.” the Suppression of metastases by a Lewis lung carcinoma. Cell, Biochimica et Biophysica Acta, 1422:207-234 (1999). 79(2):315-28 (1994). Folkman, J., “Tumor angiogenesis.” The Molecular Basis of Cancer O'Reilly, "Endostatin: an endogenous inhibitor of angiogenesis and (eds. Mendelsohn, J. Howley, P. M., Israel, M. A. & Liotta, L. A.) tumor growth.” Cell, 88(2):277-85 (1997). 206-232 (1995). Rarey et al., “A Fast Flexible Docking Method Using an Incremental Gaits et al., “Increase in Receptor-like Protein Tyrosine Phosphatase Construction Algorithm.” J. Mol. Biol., 261:470-489 (1996). Activity and Express Level on Density-Dependent Growth Arrest of Riechmann et al., “Reshaping Human Antibodies for Therapy.” Endothelial Cells.” Biochem J., 311.97-103 (1995). Nature, 332:323-327 (1988). Goodford, "A Computational Procedure for Determining Energeti Saliba, "Heparin in the Treatment of Burns: A Review.” May 2001; cally Favorable Binding Sites on Biologically Important Macromol Burn 27(4):349-358; full text edition, pp. 1-16. ecules,” J. Med. Chem. 28(7):849-57 (1985).